首页 | 本学科首页   官方微博 | 高级检索  
相似文献
 共查询到10条相似文献,搜索用时 109 毫秒
1.
In the current study, we aimed to investigate the effect of saffron supplementation on glycemic status, lipid profile, atherogenic indices, and oxidative status in patients with type-2 diabetes (T2DM). In a randomized, double-blind controlled trial, 70 patients were randomly allocated into two groups (n = 35, each) and received 100 mg/day of saffron or placebo for eight weeks. Dietary intake, weight, body mass index (BMI), waist and hip circumferences (WC and HC), waist to hip ratio (WHR), fasting blood sugar (FBS), hemoglobin A1c (HbA1c), insulin, and Homeostatic model assessment for insulin resistance (HOMA-IR), lipid profile, atherogenic indices, oxidative status, and liver enzymes were determined before and after the intervention. At the end of the eighth week, saffron intervention could significantly reduce FBS (7.57%), lipid profile (except high-density lipoprotein cholesterol [HDL-C]), atherogenic indices, and liver enzymes (p < .05). Moreover, saffron could improve oxidative status (nitric oxide [NO] and malondialdehyde [MDA] reduced by 26.29% and 16.35%, respectively). Catalase (CAT) concentration remained unchanged. Saffron supplementation may alleviate T2DM by improving glycemic status, lipid profile, liver enzymes, and oxidative status. Further investigation is necessary to assess possible side effects and confirm the positive effect of saffron as a complementary therapy in clinical recommendations for T2DM.  相似文献   

2.
目的 研究三黄降糖方对糖尿病大鼠心肌病变的作用及对心肌肾素一血管紧张素系统(RAS)的影响。方法 腹腔注射链脲菌素(STZ)造成大鼠糖尿病模型,于造模后2周起分别灌胃三黄降糖方(50g/kg)、达美康(20mg/kg)、卡托普利(15mg/kg)和尼群地平(30mg/kg),连续8周,检测空腹血糖、血清胰岛素(Ins)、心脏/体重比值及心肌血管紧张素Ⅱ(AngⅡ)、血管紧张素转换酶(AC:E)和醛固酮(ALD),以逆转录一聚合酶链式反应(RT-PCR)检测心肌血管紧张素Ⅰ型受体(ATIR)mRNA表达。结果 与正常对照组比较,模型对照组空腹血糖升高(P<0.01),血清Ins水平降低(P<0.01),心脏/体重比值升高(P<0.01),心肌AngⅡ含量增加(P<0.01),ACE活性升高(P<0.01),ALD含量增加(P<0.05),心肌ATIR mRNA表达增加(P<0.05)。三黄降糖方、达美康、卡托普利和尼群地平均可使模型大鼠血糖轻微降低,但各药均不升高血清Ins水平。三黄降糖方、达美康、卡托普利和尼群地平均可使心脏/体重比值下降,心肌AngⅡ含量、ACE活性和ATIR mRNA表达量均下降,三黄降糖方和卡托普利还可使心肌ALD含量降低。结论 在糖尿病病程10周,可引起心肌肥大,心脏局部RAS激活与糖尿病心肌病变的发生有关;三黄降糖方、达美康、卡托普利和尼群地平均可对抗糖尿病心肌病变,其作用与抑制心脏局部RAS激活有关。  相似文献   

3.
目的 :研究 2型糖尿病血瘀证与非血瘀证患者血清瘦素水平的变化及意义。方法 :采用放射免疫法测定 6 0例 2型糖尿病血瘀证与 10 6例 2型糖尿病非血瘀证患者的血清瘦素水平 ,观察其与性别、年龄、体重指数(BMI)、脂肪百分比 (% Fat)、空腹血糖 (FBS)、总胆固醇 (TC)、高密度脂蛋白胆固醇 (HDL - C)、低密度脂蛋白胆固醇 (L DL - C)、三酰甘油 (TG)、内皮素 (ET)、血浆胰岛素 (INS)等指标的关系。结果 :血瘀证与非血瘀证患者年龄和HDL - C二项指标差异显著 (P<0 .0 1) ;多元线性相关结果显示瘦索与 ET、INS、TG呈正相关 ;在逐步回归分析中FBS、HDL - C、ET、TC最后进入方程。结论 :2型糖尿病血瘀证与非血瘀证患者的血清瘦素水平变化不大 ;FBS、HDL - C、ET、TC、INS等是与血清瘦素水平变化的主要相关因素  相似文献   

4.
The efficacy of spirulina platensis (S. platensis) as an add-on therapy to metformin and its effect on atherogenic keys in patients with uncontrolled Type 2 Diabetes Mellitus (T2DM) was evaluated. Sixty patients were randomly assigned to S. platensis (2 g/day) or placebo group for three months while continuing metformin as their usual treatment. The efficacy of S. platensis was determined using the pre- and post-intervention HbA1c levels (primary outcome) as well as tracking FBS and lipid profiles levels (TC, LDL-C, TG, and HDL-C) as secondary outcomes at the different treatment time points (0,30,60,90 days). During the three–month intervention period, supplementation with S. platensis resulted in a significant lowering of HbA1c (↓1.43, p < 0.001) and FBS (↓ 24.94 mg/dL, p < 001) levels. Mean TG in the intervention group was found to be significantly lower in the intervention group than in controls (p < 0.001). Total cholesterol (TC) and its fraction, LDL-C, exhibited a fall (↓41.36 mg/dL and ↓38.4 mg/dL, respectively; p < 0.001) coupled with a marginal increase in the level of HDL-C (↑3 mg/dL; p < 0.001). Add-on therapy with S. platensis was superior to metformin regarding long-term glucose regulation and controlling blood glucose levels of subjects with T2DM. Also, as a functional supplement, S. platensis has a beneficial effect on atherogenic keys (TG and HDL-C) with no adverse events.  相似文献   

5.
Oxidative stresses are increasingly implicated in the pathogenesis of diabetic complications which may either cause direct pancreatic beta-cell damage or lead to metabolic abnormalities that can induce or aggravate diabetes. The valuable effect of antioxidant nutrients on the glycemic control of diabetic patients has been reported in experimental and clinical studies. The present study was designed to investigate the effects of the herbal medicine, Silybum marianum seed extract (silymarin), which is known to have antioxidant properties on the glycemic profile in diabetic patients. A 4-month randomized double-blind clinical trial was conducted in 51 type II diabetic patients in two well-matched groups. The first group (n = 25) received a silymarin (200 mg) tablet 3 times a day plus conventional therapy. The second group (n = 26) received the same therapy but a placebo tablet instead of silymarin. The patients were visited monthly and glycosylated hemoglobin (HbA(1)c), fasting blood glucose (FBS), insulin, total cholesterol, LDL and HDL, triglyceride, SGOT and SGPT levels were determined at the beginning and the end of the study. The results showed a significant decrease in HbA(1)c, FBS, total cholesterol, LDL, triglyceride SGOT and SGPT levels in silymarin treated patients compared with placebo as well as with values at the beginning of the study in each group. In conclusion, silymarin treatment in type II diabetic patients for 4 months has a beneficial effect on improving the glycemic profile.  相似文献   

6.
Objective. The safe and efficacious use of Pycnogenol® (French maritime pine bark extract) in other inflammatory diseases prompted this study of its antiinflammatory effects in patients with osteoarthritis (OA). The aim of the study was to evaluate whether Pycnogenol® reduces the symptoms of OA in a double‐blind, placebo‐controlled, randomly allocated trial with patients suffering from knee osteoarthritis stages I and II. Methods. 100 patients were treated for 3 months either by 150 mg Pycnogenol® per day at meals or by placebo. Patients had to report any change of use of previously prescribed antiinflammatory medication during the study period. Patients filled the Western Ontario and Mc Masters University (WOMAC) questionnaire for osteoarthritis every 2 weeks and evaluated weekly pain symptoms using a visual analogue scale for pain intensity. Results. Following treatment with Pycnogenol® patients reported an improvement of WOMAC index (p < 0.05), and a significant alleviation of pain by visual analogue scale (p < 0.04), the placebo had no effect. The use of analgesics diminished in the verum group but increased under the placebo. Treatment with Pycnogenol® was well tolerated. Conclusion. Results show that Pycnogenol® in patients with mild to moderate OA improves symptoms and is able to spare NSAIDs. Copyright © 2008 John Wiley & Sons, Ltd.  相似文献   

7.
目的观察糖敏灵丸对新诊断2型糖尿病伴代谢综合征患者β细胞功能的影响。方法采用随机、双盲、安慰剂对照的研究方法 ,纳入80例患者,随机分为治疗组(口服糖敏灵丸)及对照组(口服安慰剂),比较服药12周前后患者糖化血红蛋白、空腹血糖、餐后2小时血糖、腰围、体重指数、血脂、血压及胰岛素抵抗指数(HOMA2-IR)、胰岛素敏感指数(HOMA2-S)、胰岛β细胞功能指数(HOMA2-B)的变化。结果糖敏灵丸可有效控制患者的空腹、餐后血糖和糖化血红蛋白,同时减小患者的腰围,改善HOMA2-IR、HOMA2-S、HOMA2-B水平,但对血压和血脂的影响不显著。结论糖敏灵丸可明显改善新诊断2型糖尿病伴代谢综合征患者的各项指标,保护胰岛β细胞功能。  相似文献   

8.
黄连解毒汤对2型糖尿病大鼠血管内皮功能的影响   总被引:25,自引:3,他引:25  
目的:通过观察黄连解毒汤对2型糖尿病大鼠血管内皮功能的影响,探讨黄连解毒汤对2型糖尿病血管并发症的防治意义及其机制。方法:采用小剂量链脲佐菌尾静脉注射加高糖高热量饲料喂养的方法建立2型糖尿病大鼠模型,将模型动物随机分为模型组、黄连解毒汤组、阿司匹林组,另设正常对照组。药物干预治疗9周后,各组动物进行口服糖耐量实验(OGTT);10周后,观察各组动物体重变化并检测各组空腹血糖(FBG)、总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白-胆固醇(HDL-C)、空腹血清胰岛素(FINS)值及血清一氧化氮(NO)、血浆内皮素(ET)、血管紧张素Ⅱ(AngⅡ),von Willebrand因子(vWF)的表达水平。结果:黄连解毒汤组OGTT较模型组改善,体重,TC,TG,ET值均低于模型组(P<0.05),HDL-C和NO值高于模型组(P<0.05);FBG,FINS,AngⅡ,vWF值均显著低于模型组(P<0.01)。与阿司匹林组相比,黄连解毒汤组FBG值显著降低(P<0.05),TG,HDL-C,NO,AngⅡ,vWF的改善情况优于阿司匹林组,但无显著性差异(P>0.05)。结论:黄连解毒汤对2型糖尿病早期出现的血管内皮损伤有良好的保护作用,机制与其降糖、降脂、抗炎、改善胰岛素抵抗及内皮依赖性的舒张血管等作用有关。  相似文献   

9.
Dianex, a polyherbal formulation consisting of the aqueous extracts of Gymnema sylvestre, Eugenia jambolana, Momordica charantia Azadirachta indica, Cassia auriculata, Aegle marmelose, Withania somnifera and Curcuma longa was screened for hypoglycemic activity in normal and streptozotocin induced diabetic mice. Dianex was administered in different doses of 100-500 mg/kg/day orally in acute (6 h) and long-term (6 weeks) studies. Blood glucose levels were checked 2-6 h after treatment in acute studies and every 2 weeks in long-term studies. Body weight was recorded on the first and final day of the treatment in the long-term studies with diabetic mice. After 6 weeks, high-density lipoprotein, triglycerides, total cholesterol, alanine transaminase (ALT), aspertate transaminase (AST), urea and creatinine were estimated in serum of the diabetic mice. Glycogen and total protein levels were estimated in the liver. Also, the liver and pancreas was subjected to histological examination. Oral glucose tolerance and in vitro free radical scavenging activity was also studied.Dianex produced significant (p<0.05) hypoglycemic activity at 250-500 mg/kg doses in both normal and diabetic mice in acute and long-term studies. The body weight of diabetic mice significantly (p<0.05) increased with all tested doses of Dianex. The elevated triglycerides, cholesterol, ALT, AST, urea and creatinine levels in diabetic mice were significantly (p<0.05) reduced at the doses of 250 and 500 mg/kg. The liver glycogen and protein levels were both significantly (p<0.05) increased in diabetic mice at 250 and 500 mg/kg doses. Dianex increased the glucose tolerance significantly (p<0.05) in both normal and diabetic mice at all the doses tested. Histopathological examination showed that the formulation decreased streptozotocin induced injury to the tissues at all the doses tested. It produced significant (p<0.05) free radical scavenging activity against ABTS+, DPPH and hydroxyl free radicals at the concentrations ranging between 10-1000 microg/ml.Thus, in the present study, Dianex produced significant hypoglycemic activity in both normal and diabetic animals. It also reversed other diabetic complications in diabetic mice at 250 and 500 mg/kg doses. In our earlier study, Dianex was well tolerated in laboratory animals at higher doses (upto 10 g/kg in mice, acute toxicity; up to 2.5 g/kg in rats, subacute toxicity studies for 30 days) without exhibiting any toxic manifestation. Hence, Dianex may be useful in the treatment of diabetes mellitus.  相似文献   

10.
目的:观察小剂量普伐他汀联合丹田降脂丸治疗混合型高血脂症的临床疗效及安全性。方法:混合型高血脂症患者192例,随机分为3组各64例,西药组采用小剂量普伐他汀治疗,中药组采用丹田降脂丸治疗,联合组采用小剂量普伐他汀联合丹田降脂丸治疗,治疗12周;12周时西药组、中药组血脂水平未全部达标者再随机分为3组,改联合组采用小剂量普伐他汀联合丹田降脂丸治疗,改西药组采用常规剂量普伐他汀治疗,改中药组采用丹田降脂丸治疗,再治疗12周。观察治疗前后血脂水平的变化及不良反应。结果:治疗12周后,3组血清总胆固醇(TC)、低密度脂蛋白胆固醇(LDL—C)、高密度脂蛋白胆固醇(HDL—C)、甘油三酯(TG)水平均有不同程度的改善;3组治疗后比较,差异有显著性意义(P〈0.05),联合组TC、LDL—C、TG3项水平下降的幅度及HDL—C升高的幅度均大于西药组、中药组(P〈0.05)。改联合组TC及LDL—C下降的幅度小于改西药组,但2组比较,差异无显著性意义(P〉0.05),而改联合组TG下降的幅度及HDL—C升高幅度大于改西药组(P〈0.01):改联合组TC、LDL—C降低的幅度大于改中药组(P〈0.01),降低TG及升高LDL—C的幅度也大于改中药组(P〈0.05)。结论:小剂量普伐他汀与丹田降脂丸联合用药治疗混合型高血脂症,较单独用药更有效,可全面改善血脂水平,具有良好的安全性和耐受性。  相似文献   

设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号